Advanced Solid Tumor Clinical Trials in Fairfax, Virginia

33 studies are recruiting for advanced solid tumor in Fairfax, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. Study of AVZO-021 in Patients With Advanced Solid Tumors

   This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   13 in total

   Run by

   Avenzo Therapeutics, Inc.

   See if you can join NCT05867251 on ClinicalTrials.gov

2. First in Human, Dose Escalation Study of AN4005

   Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of AN4005. Except for Dose Level 0 (50 mg), a traditional "3 +…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Next Virginia, Fairfax, Virginia

   Locations

   7 in total

   Run by

   Adlai Nortye Biopharma Co., Ltd.

   See if you can join NCT04999384 on ClinicalTrials.gov

3. A Study of LM-24C5 For Advanced Solid Tumors

   To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Virginia Cancer Specialists, P.C., Fairfax, Virginia

   Locations

   6 in total

   Run by

   LaNova Medicines Limited

   See if you can join NCT06187402 on ClinicalTrials.gov

4. A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

   This is the first-in-human, multicenter, open-label Phase I/II study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of FB849 alone and in combination with pembrolizumab in subjects with advanced solid tumors for whom no standard therapy is…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Next Oncology Virginia, Fairfax, Virginia

   Locations

   5 in total

   Run by

   1ST Biotherapeutics, Inc.

   See if you can join NCT05761223 on ClinicalTrials.gov

5. Study of SGR-3515 In Participants With Advanced Solid Tumors.

   The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   14 in total

   Run by

   Schrödinger, Inc.

   See if you can join NCT06463340 on ClinicalTrials.gov

6. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

   TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The s…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Next Oncology, Fairfax, Virginia

   Locations

   4 in total

   Run by

   Shanghai Allink Biotherapeutics Co., Ltd.

   See if you can join NCT06707610 on ClinicalTrials.gov

7. A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

   This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subje…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   4 in total

   Run by

   OncoResponse, Inc.

   See if you can join NCT06090266 on ClinicalTrials.gov

8. A Study in Patients With Advanced Cancers

   A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology Virginia, Fairfax, Virginia

   Locations

   3 in total

   Run by

   BiOneCure Therapeutics Inc.

   See if you can join NCT05320588 on ClinicalTrials.gov